DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key esophageal cancer patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download. Use the extended worldwide coverage data set to:

  • View 10-year forecasts of the first-line drug-treatable population and diagnosed incident cases for all 171 countries, stratified by region and World Bank income status.
  • Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
  • Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
  • Generate and export global heat maps of disease risk or patient population size.

The extended worldwide coverage dashboard is available as an Excel file in the “Downloads” section. It is available only to clients with subscriptions to all 45 countries covered by DRG Epidemiology. For subscription and entitlement queries, please contact questions@teamdrg.com.

Table of contents

  • Esophageal Cancer - Epidemiology - Extrapolated Worldwide Coverage
    • Extrapolated Worldwide Coverage
      • Esophageal Cancer Extrapolated Worldwide Coverage

Author(s): Mudasir Khan, M.P.H.; Abey John, MPH

Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.

Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.


Related Reports

Gastroesophageal Cancer - Landscape & Forecast - Disease Landscape & Forecast

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma&mdas...

View Details

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma and Esophageal Cancer | Disease Landscape & Forecast | G7 | 2020

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—continues to rise; however, treatment options remain limi...

View Details

Gastroesophageal Cancer - Geographic Focus: China - Gastric Cancer - China In-Depth (China)

China has the highest incidence of gastric and GEJ adenocarcinoma globally, and therapeutic options are limited. Only three targeted agents are approved to treat this indication—Roche’s...

View Details

Gastroesophageal Cancer - Unmet Need - Detailed, Expanded Analysis (US & EU) Previously Treated Metastatic Gastric And Gastroesophageal Junction (GEJ) Adenocarcinoma

While the incidence of gastric and GEJ adenocarcinoma continues to rise, efficacious treatment options, especially in the previously treated metastati...

View Details